COMP <GO>
HBIO vs PRPO // PIOTROSKI F-SCORE QUALITY
Harvard Bioscience Inc. (NASDAQ) VS. Precipio Inc. (NASDAQ) • 15-METRIC TALLY: HBIO 4
— PRPO 5
▲ PIOTROSKI F-SCORE QUALITY LEADER: PRPO
LAST: $8.80 (+4.51%) • MKT CAP: $40.1M
piotroski-score
5/9
LAST: $19.35 (+3.59%) • MKT CAP: $34.6M
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HBIO VS. PRPO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HBIO | PRPO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.70% | 44.20% | +13.50 | HBIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -7.90% | -27.10 | PRPO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 13.66% | 1.04% | +12.62 | HBIO | /fcf-yield <GO> |
| Operating Margin | -56.10% | -5.00% | -51.10 | PRPO | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -1.50% | -58.50 | PRPO | /net-margins <GO> |
| Revenue Growth (YoY) | -8.10% | 30.50% | -38.60 | PRPO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 8/9 | -3.00 | PRPO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.9 | 36.2 | +28.70 | HBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.1M | $34.6M | $5.4M | HBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HBIO REV | PRPO REV | HBIO GROSS % | PRPO GROSS % | HBIO FCF | PRPO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $86.5M | $24.2M | 57.7% | 44.2% | $5.5M | $359.0K |
| FY 2024 | $94.1M | $18.6M | 58.2% | 40.7% | -$1.2M | $216.0K |
| FY 2023 | $112.3M | $15.4M | — | — | $14.0M | -$3.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HBIO // BETA —
PRPO // BETA —